Kiora Pharmaceuticals Inc
7EY
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
169 Saxony Road
Suite 212
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.00 | 14.60 | 0.16% |
| CAC 40 | 8,384.01 | 33.14 | 0.40% |
| DAX 40 | 24,894.01 | 258.71 | 1.05% |
| Dow JONES (US) | 51,786.90 | 584.64 | 1.14% |
| FTSE 100 | 10,430.62 | 41.10 | -0.39% |
| HKSE | 24,842.67 | 124.57 | 0.50% |
| NASDAQ | 26,653.86 | 765.02 | 2.96% |
| Nikkei 225 | 69,317.50 | 3,297.46 | 4.99% |
| NZX 50 Index | 13,360.59 | 33.28 | -0.25% |
| S&P 500 | 7,559.49 | 128.03 | 1.72% |
| S&P/ASX 200 | 8,914.00 | 7.00 | 0.08% |
| SSE Composite Index | 4,096.47 | 64.96 | 1.61% |